ACTINIUM PHARMACEUTICALS overview

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 PR Newswire NEW YORK, Nov. 18, 2024 - Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes - Two...

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors PR Newswire NEW YORK, Nov. 4, 2024 - Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM PR Newswire NEW YORK, Sept. 25, 2024 NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Actinium and...

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology PR Newswire NEW YORK, Sept. 20, 2024 Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM PR Newswire NEW YORK, Sept. 17, 2024 NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Actinium and...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM PR Newswire NEW YORK, Sept. 9, 2024 NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Actinium and certain...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM PR Newswire NEW YORK, Sept. 3, 2024 NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Actinium and certain...